Clinical trial
ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.
NCT00272064 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00272064 |
|---|---|
| Title | ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus. |
| Official title | Optimisation of Insulin Treatment of Type 2 Diabetes Mellitus by Telecare Assistance for Self Monitoring of Blood Glucose (SMBG). |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin glulisine, Insulin glargine, Metformin |
| Enrollment | 352 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 4, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: